The cell and gene therapy (CGT) field has entered a distinct phase of maturation. Following a period of rapid expansion and investment, the sector is consolidating. This new stage presents a complex paradox: extraordinary scientific progress coincides with a troubling trend of financially driven deprioritisation for promising therapies, particularly for ultra-rare diseases. For senior leaders in biopharma, investment, and policy, understanding this dynamic is crucial. Successfully navigating cell gene therapy maturation requires new models to bridge the gap between scientific promise and commercial viability.

The Maturation Paradox: Selective Investment Amid Scientific Growth

The initial wave of enthusiasm for CGT, marked by a proliferation of biotech startups and diverse capital, has subsided. According to David Barrett, CEO of the American Society of Gene & Cell Therapy (ASGCT), the field is now seeing strategic portfolio adjustments. Some developers have exited, while others are expanding their commitments. This shift signifies a move towards greater selectivity rather than a decline in the sector’s potential.

Concurrently, scientific output continues to rise. ASGCT reports record-breaking abstract submissions for its annual meeting, indicating robust research activity. Yet, investment patterns have changed. Although the number of active programmes remains stable, overall funding has contracted. Investors are now channelling capital into assets with clearer commercial pathways, often leaving scientifically validated therapies for small patient populations without financial support. This creates a critical viability gap that threatens the field’s ethical foundation and long-term progress.

Bridging the Viability Gap for Ultra-Rare Diseases

The deprioritisation of therapies for ultra-rare conditions represents a significant systemic challenge. When a programme demonstrates medical promise but is abandoned for market-size reasons, patient populations lose potential treatments. ASGCT estimates over 100 such therapies are currently at risk. To address this, innovative, non-traditional financing models are emerging.

One prominent initiative is the Cell and Gene Therapy Exchange (CGTxchange), founded by ASGCT and the Orphan Therapeutics Accelerator. This platform functions as a curated marketplace to connect deprioritised assets with alternative capital sources. Potential investors include patient advocacy organisations, charitable foundations, family offices, and venture philanthropy groups. Furthermore, artificial intelligence tools are employed to analyse regulatory dossiers, providing streamlined risk assessments to accelerate investor decision-making. This approach aims to create a distributed investment ecosystem that can advance therapies deemed commercially pre-viable under traditional models.

Systemic Challenges: Manufacturing, Delivery, and Regulation

Beyond financing, scaling CGTs faces persistent logistical and regulatory hurdles. Manufacturing complexity, especially for viral vectors, remains a bottleneck. However, progress is evident in next-generation delivery platforms, such as lipid nanoparticles, which offer potential for more scalable production. Moreover, advances in gene-modified cell therapies are enabling a shift from inpatient to outpatient administration, which could expand treatment capacity and accessibility.

On the regulatory front, policy evolution is essential for maintaining a competitive edge. The US Food and Drug Administration’s (FDA) exploration of a ‘plausible mechanism’ pathway for very small populations and its stated flexibility on Chemistry, Manufacturing, and Controls (CMC) requirements are positive developments. These adaptive approaches can help streamline development for targeted therapies while upholding safety standards, cementing a leadership position in cell gene therapy maturation amid global competition.

Sustaining Momentum in a Consolidating Field

The future of CGT remains promising, with pipelines expanding into metabolic diseases, solid tumours, and neurological disorders. Sustaining this momentum, however, demands a concerted, collaborative effort. Key actions include supporting alternative financing platforms, advocating for adaptive regulatory frameworks, and continuing investment in manufacturing innovation and clinical workforce training. A focus on equitable access must be integral from clinical trial design through to pricing and reimbursement strategies.

The current phase is not a downturn, but a necessary consolidation. By developing innovative financial instruments, advocating for smart policy, and advancing manufacturing science, the ecosystem can ensure that the remarkable engine of CGT discovery delivers its full potential to patients. The sector’s maturation, if steered effectively, will lay a sustainable foundation for the next wave of transformative therapies.

Reference